| Name | Title | Contact Details |
|---|
CALIBER THERAPEUTICS is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Care Services is a Eastlake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Halo Pharmaceutical is a contract development and manufacturing organization (CDMO) that provides scientific, regulatory and development expertise as well as a wide spectrum of manufacturing services to help customers bring their products to market quickly, effectively and on budget. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV designations. Halo Pharmaceutical’s capabilities in the areas of tech transfer, process and product development, production, scale-up and validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way.
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.